$375 Million is the total value of CHI Advisors LLC's 23 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 16.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RXDX | Sell | PROMETHEUS BIOSCIENCES INC | $101,618,000 | +7.5% | 923,800 | -42.3% | 27.06% | +6.5% |
| PLRX | Sell | PLIANT THERAPEUTICS INC | $61,274,012 | -14.0% | 3,169,892 | -7.0% | 16.32% | -14.8% |
| VECT | Buy | VECTIVBIO HLDG AG | $47,595,916 | +92.6% | 5,492,893 | +33.3% | 12.68% | +90.7% |
| RPTX | Sell | REPARE THERAPEUTICS INC | $41,189,854 | +10.6% | 2,800,126 | -8.8% | 10.97% | +9.6% |
| CGEM | Buy | CULLINAN ONCOLOGY INC | $35,000,089 | -15.8% | 3,317,544 | +2.3% | 9.32% | -16.6% |
| LRMR | Buy | LARIMAR THERAPEUTICS INC | $14,345,001 | +31.3% | 3,473,366 | +1.7% | 3.82% | +30.1% |
| CMPX | COMPASS THERAPEUTICS INC | $14,233,452 | +120.6% | 2,829,712 | 0.0% | 3.79% | +118.5% | |
| KZR | Buy | KEZAR LIFE SCIENCES INC | $13,301,735 | -12.4% | 1,889,451 | +7.2% | 3.54% | -13.2% |
| KROS | Buy | KEROS THERAPEUTICS INC | $10,327,133 | +37.1% | 215,059 | +7.4% | 2.75% | +35.8% |
| OMEGA THERAPEUTICS INC | $6,029,085 | +5.3% | 1,055,882 | 0.0% | 1.61% | +4.4% | ||
| Buy | RALLYBIO CORP | $4,770,536 | +69.7% | 726,109 | +273.7% | 1.27% | +68.1% | |
| IKNA | Buy | IKENA ONCOLOGY INC | $4,355,409 | +1.0% | 1,637,372 | +34.8% | 1.16% | +0.1% |
| DTIL | Sell | PRECISION BIOSCIENCES INC | $4,224,286 | -11.6% | 3,549,820 | -3.4% | 1.12% | -12.4% |
| Sell | 2SEVENTY BIO INC | $3,122,571 | -59.5% | 333,252 | -37.1% | 0.83% | -59.9% | |
| ORTX | ORCHARD THERAPEUTICS PLCspon ads | $2,963,323 | -25.8% | 7,987,396 | 0.0% | 0.79% | -26.5% | |
| INZY | Buy | INOZYME PHARMA INC | $2,315,120 | -56.7% | 2,204,876 | +10.4% | 0.62% | -57.1% |
| FRLN | FREELINE THERAPEUTICS HLDGSsponsored ads | $2,287,331 | -32.1% | 4,814,419 | 0.0% | 0.61% | -32.8% | |
| CRVS | CORVUS PHARMACEUTICALS INC | $2,026,742 | +3.8% | 2,384,402 | 0.0% | 0.54% | +2.9% | |
| GTHX | Buy | G1 THERAPEUTICS INC | $1,813,321 | -55.2% | 333,945 | +3.1% | 0.48% | -55.6% |
| OVID | OVID THERAPEUTICS INC | $1,608,569 | +1.1% | 864,822 | 0.0% | 0.43% | 0.0% | |
| ONCR | ONCORUS INC | $599,672 | -70.2% | 2,367,436 | 0.0% | 0.16% | -70.4% | |
| LABD | Sell | DIREXION SHS ETF TRdaily s&p biotec | $431,250 | -64.0% | 25,000 | -50.0% | 0.12% | -64.3% |
| PLRX | New | PLIANT THERAPEUTICS INCcall | $29,250 | – | 30,000 | +100.0% | 0.01% | – |
| NKTX | Exit | NKARTA INC | $0 | – | -117,599 | -100.0% | -0.42% | – |
| EIGR | Exit | EIGER BIOPHARMACEUTICALS INC | $0 | – | -455,100 | -100.0% | -0.92% | – |
| AKUS | Exit | AKOUOS INC | $0 | – | -1,288,358 | -100.0% | -2.34% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.